Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models

Authors: Lays M Sobral, Lucas O Sousa, Ricardo D Coletta, Hamilton Cabral, Lewis J Greene, Eloiza H Tajara, J Silvio Gutkind, Carlos Curti, Andréia M Leopoldino

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

SET/I2PP2A is a multifunctional protein that is up-regulated in head and neck squamous cell carcinoma (HNSCC). The action of SET in HNSCC tumorigenicity is unknown.

Methods

Stable SET knockdown by shRNA (shSET) was established in three HNSCC cell lines: HN12, HN13, and Cal27. Protein expression and phosphorylated protein levels were determined by Western blotting and immunofluorescence, cell migration and invasion were measured by functional analysis, and PP2A activity was determined using a serine/threonine phosphatase assay. A real-time PCR array was used to quantify 84 genes associated with cell motility. Metalloproteinase (MMP) activity was assessed by zymographic and fluorometric assays. HN12shSET xenograft tumors (flank and tongue models) were established in Balb/c nude mice; the xenograft characteristics and cisplatin sensitivity were demonstrated by macroscopic, immunohistochemical, and histological analyses, as well as lymph node metastasis by histology.

Results

The HN12shSET cells displayed reduced ERK1/2 and p53 phosphorylation compared with control. ShSET reduced HN12 cell proliferation and increased the sub-G1 population of HN12 and Cal27 cells. Increased PP2A activity was also associated with shSET. The PCR array indicated up-regulation of three mRNAs in HN12 cells: vimentin, matrix metalloproteinase-9 (MMP9) and non-muscle myosin heavy chain IIB. Reduced E-cadherin and pan-cytokeratin, as well as increased vimentin, were also demonstrated as the result of SET knockdown. These changes were accompanied by an increase in MMP-9 and MMP-2 activities, migration and invasion. The HN12shSET subcutaneous xenograft tumors presented a poorly differentiated phenotype, reduced cell proliferation, and cisplatin sensitivity. An orthotopic xenograft tumor model using the HN12shSET cells displayed increased metastatic potential.

Conclusions

SET accumulation has important actions in HNSCC. As an oncogene, SET promotes cell proliferation, survival, and resistance to cell death by cisplatin in vivo. As a metastasis suppressor, SET regulates invasion, the epithelial mesenchymal transition, and metastasis.
Appendix
Available only for authorised users
Literature
1.
Adachi Y, Pavlakis GN, Copeland TD: Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem. 1994, 269: 2258-2262.PubMed
2.
Li M, Makkinje A, Damuni Z: The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996, 271: 11059-11062. 10.1074/jbc.271.19.11059CrossRefPubMed
3.
Van Kanegan MJ, Adams DG, Wadzinski BE, Strack S: Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt. J Biol Chem. 2005, 280: 36029-36036. 10.1074/jbc.M506986200CrossRefPubMed
4.
Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW: Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2008, 283: 1882-1892. 10.1074/jbc.M709585200CrossRefPubMed
5.
Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Polizello AC, Uyemura SA, Tajara EH, Gutkind JS, Curti C: Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. Mol Cell Biochem. 2012, 363: 65-74. 10.1007/s11010-011-1158-xCrossRefPubMed
6.
Wada T, Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004, 23: 2838-2849. 10.1038/sj.onc.1207556CrossRefPubMed
7.
Fukukawa C, Shima H, Tanuma N, Okada T, Kato N, Adachi Y, Kikuchi K: The oncoprotein I-2PP2A/SET negatively regulates the MEK/ERK pathway and cell proliferation. Int J Oncol. 2005, 26: 751-756.PubMed
8.
Jenkins LM, Durell SR, Mazur SJ, Appella E: p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis. 2012, 33: 1441-1449. 10.1093/carcin/bgs145PubMedCentralCrossRefPubMed
9.
Taira N, Yoshida K: Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol Histopathol. 2012, 27: 437-443.PubMed
10.
Estanyol JM, Jaumot M, Casanovas O, Rodriguez-Vilarrupla A, Agell N, Bachs O: The protein SET regulates the inhibitory effect of p21(Cip1) on cyclin Ecyclin-dependent kinase 2 activity. J Biol Chem. 1999, 274: 33161-33165. 10.1074/jbc.274.46.33161CrossRefPubMed
11.
Liu GP, Wei W, Zhou X, Zhang Y, Shi HH, Yin J, Yao XQ, Peng CX, Hu J, Wang Q, HL Li, Wang JZ: I(2)(PP2A) regulates p53 and Akt correlatively and leads the neurons to abort apoptosis. Neurobiol Aging. 2012, 33: 254-264. 10.1016/j.neurobiolaging.2010.01.016CrossRefPubMed
12.
13.
Micalizzi DS, Farabaugh SM, Ford HL: Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010, 15: 117-134. 10.1007/s10911-010-9178-9PubMedCentralCrossRefPubMed
14.
Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, Albers AE: Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One. 2011, 6: e16466- 10.1371/journal.pone.0016466PubMedCentralCrossRefPubMed
15.
Shieh SY, Ikeda M, Taya Y, Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997, 91: 325-334. 10.1016/S0092-8674(00)80416-XCrossRefPubMed
16.
Pinho AV, Rooman I, Real FX: p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle. 2011, 10: 1312-1321. 10.4161/cc.10.8.15363CrossRefPubMed
17.
Garavello W, Maggioni D, Nicolini G, Motta L, Tredici G, Gaini R: Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study. Oncol Rep. 2010, 24: 10731078
18.
Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS: Cofilin promotes actin polymerization and defines the direction of cell motility. Science. 2004, 304: 743-746. 10.1126/science.1094561CrossRefPubMed
19.
Li R, Doherty J, Antonipillai J, Chen S, Devlin M, Visser K, Baell J, Street I, Anderson RL, Bernard O: LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice. Clin Exp Metastasis. 2013, 30: 483-495. 10.1007/s10585-012-9553-6CrossRefPubMed
20.
Zhang H, Ghai P, Wu H, Wang C, Field J, Zhou GL: Mammalian adenylyl cyclase-associated protein 1 (CAP1) regulates cofilin function, the actin cytoskeleton, and cell adhesion. J Biol Chem. 2013, 288: 28306-10.1074/jbc.A113.484535.PubMedCentralCrossRef
21.
Lee S, Helfman DM: Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem. 2004, 279: 18851891
22.
Qian HL, Peng XX, Chen SH, Ye HM, Qiu JH: p62 Expression in primary carcinomas of the digestive system. World J Gastroenterol. 2005, 11: 17881792
23.
24.
Nezis IP, Stenmark H: p62 at the interface of autophagy, oxidative stress signaling, and cancer. Antioxid Redox Signal. 2012, 17: 786-793. 10.1089/ars.2011.4394CrossRefPubMed
25.
Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP: Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011, 30: 2504-2513. 10.1038/onc.2010.622PubMedCentralCrossRefPubMed
26.
Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B: Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013, 5: 105-121. 10.1002/emmm.201201283PubMedCentralCrossRefPubMed
27.
Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D: Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013, 122: 19231934CrossRef
28.
Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N, Bachs O: The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem. 2003, 278: 1158-1164. 10.1074/jbc.M207497200CrossRefPubMed
29.
Madeira A, Pommet JM, Prochiantz A, Allinquant B: SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. FASEB J. 2005, 19: 1905-1907.PubMed
30.
Ten Klooster JP, Leeuwen I, Scheres N, Anthony EC, Hordijk PL: Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J. 2007, 26: 336-345. 10.1038/sj.emboj.7601518PubMedCentralCrossRefPubMed
31.
Lam BD, Anthony EC, Hordijk PL: Cytoplasmic targeting of the protooncogene SET promotes cell spreading and migration. FEBS Lett. 2013, 587: 111-119. 10.1016/j.febslet.2012.11.013CrossRefPubMed
32.
Almeida LO, Goto RN, Pestana CR, Uyemura SA, Gutkind S, Curti C, Leopoldino AM: SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates. FEBS J. 2012, 279: 4615-4628.CrossRefPubMed
33.
Leung JW, Leitch A, Wood JL, Shaw-Smith C, Metcalfe K, Bicknell LS, Jackson AP, Chen J: SET nuclear oncogene associates with microcephalin/MCPH1 and regulates chromosome condensation. J Biol Chem. 2011, 286: 21393-21400. 10.1074/jbc.M110.208793PubMedCentralCrossRefPubMed
34.
Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J, Curti C: SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. Oral Oncol. 2012, 48: 1106-1113. 10.1016/j.oraloncology.2012.05.014CrossRefPubMed
35.
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D: FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007, 117: 2408-2421. 10.1172/JCI31095PubMedCentralCrossRefPubMed
36.
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM: PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013, 123: 4144-4157. 10.1172/JCI68951PubMedCentralCrossRefPubMed
37.
Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE: P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003, 25: 654-661. 10.1002/hed.10274CrossRefPubMed
38.
Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M, Tsukamasa Y, Ito M, Nozawa Y: Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free Radic Res. 2011, 45: 1033-1039. 10.3109/10715762.2011.591391CrossRefPubMed
39.
Casares C, Ramírez-Camacho R, Trinidad A, Roldán A, Jorge E, García-Berrocal JR: Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur Arch Otorhinolaryngol. 2012, 269: 2455-2459. 10.1007/s00405-012-2029-0CrossRefPubMed
40.
Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, Zacksenhaus E: RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011, 10: 1563-1570. 10.4161/cc.10.10.15703CrossRefPubMed
41.
Groblewska M, Siewko M, Mroczko B, Szmitkowski M: The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 2012, 50: 12-19.CrossRefPubMed
42.
Cardinali M, Pietraszkiewicz H, Ensley JF, Robbins KC: Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int J Cancer. 1995, 61: 98-103. 10.1002/ijc.2910610117CrossRefPubMed
43.
Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012, 9: 671-675. 10.1038/nmeth.2089CrossRefPubMed
44.
Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T, Coletta RD: Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol. 2011, 47: 840-846. 10.1016/j.oraloncology.2011.06.011CrossRefPubMed
45.
Neumann-Jensen B, Holmstrup P, Pindborg JJ: Smoking habits of 611 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1977, 43: 410-415. 10.1016/0030-4220(77)90328-0CrossRefPubMed
46.
Klemencic I, Carmona AK, Cezari MH, Juliano MA, Juliano L, Guncar G, Turk D, Krizaj I, Turk V, Turk B: Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase. Eur J Biochem. 2000, 267: 5404-5412. 10.1046/j.1432-1327.2000.01592.xCrossRefPubMed
Metadata
Title
Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models
Authors
Lays M Sobral
Lucas O Sousa
Ricardo D Coletta
Hamilton Cabral
Lewis J Greene
Eloiza H Tajara
J Silvio Gutkind
Carlos Curti
Andréia M Leopoldino
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-32

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

TCAB1: a potential target for diagnosis and therapy of head and neck carcinomas

Research

NF-kappa B mediated Up-regulation of CCCTC-binding factor in pediatric acute lymphoblastic leukemia

Research

Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in Nasopharyngeal Carcinoma via activation of NF-κB pathway

Short communication

Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization

Short communication

Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases

Research

RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits